Riverview Trust Co raised its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 27.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,629 shares of the company’s stock after purchasing an additional 1,624 shares during the quarter. Johnson & Johnson accounts for approximately 1.0% of Riverview Trust Co’s holdings, making the stock its 17th biggest position. Riverview Trust Co’s holdings in Johnson & Johnson were worth $1,352,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Norges Bank bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $4,172,929,000. BlackRock Inc. grew its holdings in Johnson & Johnson by 2.6% during the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after purchasing an additional 4,982,885 shares during the period. GQG Partners LLC increased its position in Johnson & Johnson by 1,109.4% in the fourth quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock worth $676,375,000 after buying an additional 3,627,424 shares in the last quarter. State Street Corp raised its stake in shares of Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after buying an additional 2,492,359 shares during the period. Finally, National Bank of Canada FI bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $286,371,000. 68.78% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have weighed in on JNJ. Sanford C. Bernstein downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $180.00 to $183.00 in a report on Wednesday, March 16th. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Citigroup decreased their price target on Johnson & Johnson from $210.00 to $205.00 in a report on Tuesday, May 17th. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Finally, Raymond James increased their target price on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $190.50.
Shares of Johnson & Johnson stock opened at $178.50 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The firm has a market cap of $469.71 billion, a price-to-earnings ratio of 24.06, a PEG ratio of 3.52 and a beta of 0.63. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The business has a 50-day moving average price of $176.93 and a 200-day moving average price of $173.98.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. The business had revenue of $23.43 billion for the quarter, compared to the consensus estimate of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.59 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.23 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were given a dividend of $1.13 per share. The ex-dividend date was Monday, May 23rd. This represents a $4.52 annualized dividend and a yield of 2.53%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio (DPR) is 60.92%.
In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. Insiders sold a total of 78,161 shares of company stock valued at $13,895,302 over the last three months. Corporate insiders own 0.35% of the company’s stock.
Johnson & Johnson Company Profile (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also
Want More Great Investing Ideas?
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
